PMGC HOLDINGS INC (ELAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.21-0.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -40.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
ELAB — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-09-02
Material Modification to Rights of Security Holders. To the extent required by
Why it matters: Better cash flow means better financial health and efficiency. This is key for growth.
Supportive ifOperating cash flow will be positive in the earnings report on August 11, 2026.
Worry ifOperating cash flow stays negative in the earnings report.
Why it matters: A drop in revenue growth could signal a slowdown in the sector. This affects overall performance.
Worry ifRevenue growth falls below the median for the sector in the next quarter.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: Clear cash flow strategies could show better financial health and stability.
Watch forManagement shares plans to improve cash flow in the Q2 earnings call.
Also watch forManagement fails to address cash flow challenges in the Q2 earnings call.
Why it matters: Good results would support the Phase III findings. This would help develop muscle therapies.
Supportive ifTests show that ANT1 induction works in a mature muscle model.
Worry ifTests do not confirm ANT1 induction results from Phase III.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$323 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,865 loss on $10,000 · 18.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,994 loss on $10,000 · 99.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More acquisitions could show growth in PMGC's portfolio. This may boost investor confidence.
Supportive ifPMGC announces a new acquisition or merger that fits its goals.
Worry ifNo new M&A news is reported, which may show slower growth.
Why it matters: Better cash flow would show improved efficiency and financial health.
Supportive ifOperating cash flow turns positive or improves a lot from past quarters.
Worry ifOperating cash flow stays negative or gets worse compared to Q1 2026.
Why it matters: Cash flow trends show how well the company is doing. They show if it can keep operating.
Watch forPositive cash flow reported for the quarter, showing better results than before.
Also watch forThe company reported negative cash flow this quarter. This shows it has ongoing financial problems.
Why it matters: Good results would show the AI drug program and muscle preservation plan can work.
Supportive ifA press release will confirm that four AI-selected compounds move to testing in muscle models.
Worry ifNo news about progress or failure to test the compounds further.
Why it matters: This partnership could make PMGC more important in the space economy.
Supportive ifAgreements are signed for the Mice2Space study.
Worry ifThe partnership fails or is delayed more than expected.
Why it matters: New acquisitions could help growth and improve the company's biopharma skills.
Supportive ifAnnouncement of a new acquisition or merger that fits growth plans.
Worry ifNo new acquisitions or mergers are announced in the next quarter.
Why it matters: Better cash flow means the company is more efficient. It also shows better financial health.
Watch forOperating cash flow turns positive in the next financial report.
Also watch forOperating cash flow stays negative or gets worse in the next report.
Why it matters: New acquisitions will help growth. They will support management's plan for expansion.
Supportive ifAnnouncement of at least one new strategic acquisition in Q3 2026.
Worry ifNo new acquisitions announced in Q3 2026.
Why it matters: Approval would boost the company's intellectual property. It would also help future drug work.
Supportive ifThe U.S. Patent Office grants the new patent application for EL-22.
Worry ifThe patent for EL-22 is rejected or delayed.
Why it matters: Nominating a lead compound is an important step in drug development. It could prove the AI-driven method and improve the company's pipeline.
Supportive ifA lead compound was announced from the Expansion Phase III results.
Worry ifNo lead compound is nominated or the results from Phase III are unfavorable.
Why it matters: Confirming ANT1 induction in a mature muscle model is very important. It shows how well the compounds work and if they are ready for more development.
Supportive ifGood results show ANT1 activation in human muscle cells.
Worry ifResults show no clear ANT1 induction or are unclear.
Why it matters: This partnership could improve skills in aerospace and space technology. It may create new chances and ways to make money.
Supportive ifAgreements or projects with Orbit2Orbit have been announced.
Worry ifNo new news or updates about the partnership.
Why it matters: A share buyback can signal management's confidence in the company's value. It may also improve shareholder returns.
Supportive ifThe share buyback program has been announced.
Worry ifNo updates or execution of the buyback program.